Overview and Scope
Artificial intelligence (AI) in biopharmaceuticals refers to applying various AI techniques to analyze complex biological data and improve various aspects of drug discovery, development, and delivery within the pharmaceutical industry. AI in biopharmaceuticals holds great promise for revolutionizing drug discovery, development, and delivery processes by accelerating timelines, reducing costs, and improving the efficiency and effectiveness of treatments.
Sizing and Forecast
The artificial intelligence (AI) in biopharmaceuticals market size has grown exponentially in recent years. It will grow from $1.19 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 33.8%. The growth in the historic period can be attributed to advancements in computational power, biomedical data explosion, precision medicine paradigm, regulatory support and guidance.
The artificial intelligence (AI) in biopharmaceuticals market size is expected to see exponential growth in the next few years. It will grow to $4.99 billion in 2028 at a compound annual growth rate (CAGR) of 33.1%. The growth in the forecast period can be attributed to advancements in computational biology, integration of multi-modal data, convergence of ai and life sciences, regulatory support and frameworks, ethical and fair ai principles. Major trends in the forecast period include integration of multi-omics data, AI-driven drug design and discovery, explainable AI and regulatory acceptance, technological advancements, regulatory developments, and emerging opportunities.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-biopharmaceuticals-global-market-report
The artificial intelligence (AI) in biopharmaceuticals market covered in this report is segmented –
1) By Offering: Hardware, Software, Services
2) By Deployment: Cloud, On-Premises
3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies
4) By Application: Business Process And Supply Chain, Drug Discovery, Medical Imaging And Diagnostics, Precision Medicine
5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes
North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in biopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=14251&type=smp
Major Driver Impacting Market Growth
The growing prevalence of chronic diseases is expected to propel the growth of artificial intelligence (AI) in biopharmaceuticals market going forward. Chronic diseases are long-lasting conditions that generally progress slowly and may persist for years or even a lifetime. It arises from lifestyle factors, an aging population, genetic predispositions, and environmental factors. AI in biopharmaceuticals is increasingly used to manage chronic diseases because it analyzes large volumes of diverse data sources, identifies patterns, and personalizes treatment approaches. For instance, according to the National Library of Medicine, a US-based medical library, chronic diseases are expected to grow by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Therefore, the growing prevalence of chronic diseases drives the growth of artificial intelligence (AI) in the biopharmaceuticals market.
Key Industry Players
Major companies operating in the artificial intelligence (AI) in biopharmaceuticals market are Apple Inc., Google LLC, Microsoft Corporation, Tencent Holdings Limited, Amazon Web Services Inc., International Business Machines Corporation, Exscientia Limited, NVIDIA Corporation, Amgen Inc., DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.
The artificial intelligence (ai) in biopharmaceuticals market report table of contents includes:
1. Executive Summary
2. Artificial Intelligence (AI) In Biopharmaceuticals Characteristics
3. Artificial Intelligence (AI) In Biopharmaceuticals Trends And Strategies
4. Artificial Intelligence (AI) In Biopharmaceuticals – Macro Economic Scenario
5. Global Artificial Intelligence (AI) In Biopharmaceuticals Size and Growth
…..
32. Global Artificial Intelligence (AI) In Biopharmaceuticals Competitive Benchmarking
33. Global Artificial Intelligence (AI) In Biopharmaceuticals Competitive Dashboard
34. Key Mergers And Acquisitions In The Artificial Intelligence (AI) In Biopharmaceuticals
35. Artificial Intelligence (AI) In Biopharmaceuticals Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
